newest glp 1 drug With FDA approval of Wegovy pill, new era of oral GLP-1 weight loss drugs begins A new wave of weight-loss

most common AEs include nausea, vomiting, and diarrhea), room for improvement exists in improving GI tolerability and patient discontinuation due to AEs

More than weight loss, the drug has demonstrated ancillary advantages, including up to an 80% reduction in liver fat and alleviation of chronic knee pain and sleep apnea

Toxicities of opioid analgesics: respiratory depression, histamine release, hemodynamic changes, hypersensitivity, serotonin toxicity

DKD afflicts 2040% of people with T2D, and manifest as increased urinary albumin excretion, impaired GFR or a combination of both [3]

In addition, we recently addressed the underlying mechanism and potential risks of GLP-1 drug interactions in an ASCPT webinar, highlighting the effect of delayed gastric emptying: That Gut Feeling: Evaluating the Effects of Food, Gastric pH and Rate of Gastric Emptying on Oral Drug Absorption & Digging into the Impact of Concomitant GLP-1 Agonists

Who is it for: Wegovy is recommended for pre-, peri- and post-menopausal women who qualify for weight loss treatments and would benefit from a holistic platform with 24/7 access to physicians and a supportive community of experts and other women in this life stage